Vanguard Portfolio Management’s Artiva Biotherapeutics ARTV Stock Holding History

Vanguard Portfolio Management’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Buy	+31,113	New	+$283K	﹤0.01%	3096

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Portfolio Management's ARTV Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 31,113 shares worth $302K. The stake represents ﹤0.01% of the portfolio and ranks #3096 among its holdings.

72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Vanguard Portfolio Management held 31,113 shares of Artiva Biotherapeutics worth $302K as of Q2 2026.
Artiva Biotherapeutics was a new Vanguard Portfolio Management position in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3096 holding.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.